Addex Therapeutics (XSWX:ADXN) 3-Year Revenue Growth Rate : -45.40% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Addex Therapeutics 3-Year Revenue Growth Rate?

Addex Therapeutics's Revenue per Share for the three months ended in Dec. 2023 was CHF0.00.

During the past 12 months, Addex Therapeutics's average Revenue per Share Growth Rate was -29.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -45.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was -37.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Addex Therapeutics was 51.00% per year. The lowest was -56.70% per year. And the median was -32.20% per year.

Competitive Comparison of Addex Therapeutics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Addex Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Addex Therapeutics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Addex Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Addex Therapeutics's 3-Year Revenue Growth Rate falls into.

Addex Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Addex Therapeutics (XSWX:ADXN) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Addex Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Addex Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Addex Therapeutics (XSWX:ADXN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Addex Therapeutics Ltd (XSWX:ADXN) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

ADXN:USA ADXNz:UK APE1:Germany

Address

Chemin des Aulx 12, Plan-les-Ouates, P.O. Box 68, Geneva, CHE, 1202

Website

https://www.addextherapeutics.com

Addex Therapeutics Ltd is a biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe.

Addex Therapeutics (XSWX:ADXN) Headlines

From GuruFocus

Thinking about buying stock in Applovin, Sonos, WiMi Hologram Cloud, Addex Therapeutics, or Snap?

By PRNewswire PRNewswire • 02-09-2023

Enamine Extend Collaboration With Prominent Swiss Biotech

By Business Wire Business Wire • 02-24-2021